NEU neuren pharmaceuticals limited

Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-47

  1. 3,224 Posts.
    lightbulb Created with Sketch. 730
    "E&P forecast FY24 Daybue sales of US$346M which is in the upper half of ACAD’s guidance".
    I have provided some additional data that may be of use in assessing the upcoming Q4 2024 Daybue revenue that will be reported by Acadia shortly:
    *E&P forecast has effectively concluded that Q4 2024 Daybue revenue will be US$94.3M greater than the sum of the past 3 quarters to arrive at the US$346M figure.This figure is just 3.4% above the Q3 2024 revenue of US$91.2M.
    *By way of a one year on year comparison Q3 2023 Daybue revenue was US$ 87.1M.
    *In order to avoid a revenue guidance miss in a couple of weeks US$88.3M is required to get to the bottom of the Acadia 12 month guidance number of US$340M.
    Kens
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.86
Change
1.320(10.5%)
Mkt cap ! $1.702B
Open High Low Value Volume
$12.96 $14.00 $12.91 $9.892M 722.7K

Buyers (Bids)

No. Vol. Price($)
1 9 $13.84
 

Sellers (Offers)

Price($) Vol. No.
$13.87 175 1
View Market Depth
Last trade - 12.57pm 26/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.